Ingenia Therapeutics Inc. (KOSDAQ:950260)

Ingenia Therapeutics Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Sep 17, 2026	Dec 31, 2025	Dec 31, 2024
Debt / Equity Ratio	0.10	0.09	0.06
Net Debt / Equity Ratio	-0.81	-0.89	-0.76
Net Debt / EBITDA Ratio	0.51	0.55	3.38
Net Debt / FCF Ratio	0.67	0.55	1.72
Quick Ratio	1.45	2.22	4.39
Current Ratio	1.72	2.65	4.64
Return on Equity (ROE)	-	-81.50%	-
Return on Assets (ROA)	-	-48.82%	-
Return on Invested Capital (ROIC)	-551.67%	-519.35%	-69.90%
Return on Capital Employed (ROCE)	-161.70%	-161.40%	-22.40%

Yields

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Sep 17, 2026	Dec 31, 2025	Dec 31, 2024
Buyback Yield / Dilution	-	68.05%	-

Data Source: S&P Global Market Intelligence Last updated: Aug 19, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 18, 2026

Data Sources Report a data error